Connexin Lateralization Contributes to Male Susceptibility to Atrial Fibrillation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Sep 23

PMID 36142603

Authors

Simon Thibault

Anh-Tuan Ton

Francois Huynh

Celine Fiset

Affiliations

Soon will be listed here.

Abstract

Men have a higher risk of developing atrial fibrillation (AF) than women, though the reason for this is unknown. Here, we compared atrial electrical and structural properties in male and female mice and explored the contribution of sex hormones. Cellular electrophysiological studies revealed that action potential configuration, Na and K currents were similar in atrial myocytes from male and female mice (4-5 months). Immunofluorescence showed that male atrial myocytes had more lateralization of connexins 40 (63 ± 4%) and 43 (66 ± 4%) than females (Cx40: 45 ± 4%, = 0.006; Cx43: 44 ± 4%, = 0.002), with no difference in mRNA expression. Atrial mass was significantly higher in males. Atrial myocyte dimensions were also larger in males. Atrial fibrosis was low and similar between sexes. Orchiectomy (ORC) abolished sex differences in AF susceptibility (M: 65%; ORC: 38%, = 0.050) by reducing connexin lateralization and myocyte dimensions. Ovariectomy (OVX) did not influence AF susceptibility (F: 42%; OVX: 33%). This study shows that prior to the development of age-related remodeling, male mice have more connexin lateralization and larger atria and atrial myocyte than females. Orchiectomy reduced AF susceptibility in males by decreasing connexin lateralization and atrial myocyte size, supporting a role for androgens. These sex differences in AF substrates may contribute to male predisposition to AF.

Citing Articles

Enhanced Ca-Driven Arrhythmogenic Events in Female Patients With Atrial Fibrillation: Insights From Computational Modeling.

Zhang X, Wu Y, Smith C, Louch W, Morotti S, Dobrev D JACC Clin Electrophysiol. 2024; 10(11):2371-2391.

PMID: 39340505 PMC: 11602355. DOI: 10.1016/j.jacep.2024.07.020.

Sex-Based Mechanisms of Cardiac Development and Function: Applications for Induced-Pluripotent Stem Cell Derived-Cardiomyocytes.

Luo Y, Safabakhsh S, Palumbo A, Fiset C, Shen C, Parker J Int J Mol Sci. 2024; 25(11).

PMID: 38892161 PMC: 11172775. DOI: 10.3390/ijms25115964.

Synergistic Effects of Weight Loss and Catheter Ablation: Can microRNAs Serve as Predictive Biomarkers for the Prevention of Atrial Fibrillation Recurrence?.

Forster C, Kunzel S, Shityakov S, Stavrakis S Int J Mol Sci. 2024; 25(9).

PMID: 38731908 PMC: 11083177. DOI: 10.3390/ijms25094689.

Probability Score to Predict Spontaneous Conversion to Sinus Rhythm in Patients with Symptomatic Atrial Fibrillation When Less Could Be More?.

Mariani M, Pierucci N, Trivigno S, Cipollone P, Piro A, Chimenti C J Clin Med. 2024; 13(5).

PMID: 38592704 PMC: 10934271. DOI: 10.3390/jcm13051470.

Effects of Sex on the Susceptibility for Atrial Fibrillation in Pigs with Ischemic Heart Failure.

Pauly V, Vlcek J, Zhang Z, Hesse N, Xia R, Bauer J Cells. 2023; 12(7).

PMID: 37048048 PMC: 10093477. DOI: 10.3390/cells12070973.

References

Guerra F, Ciliberti G, Capucci A . Sex differences in atrial fibrillation: The case of testosterone. Eur J Prev Cardiol. 2018; 25(11):1131-1132. DOI: 10.1177/2047487318784741. View

Magnani J, Moser C, Murabito J, Sullivan L, Wang N, Ellinor P . Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study. Circ Arrhythm Electrophysiol. 2014; 7(2):307-12. PMC: 4035016. DOI: 10.1161/CIRCEP.113.001322. View

Westerman S, Wenger N . Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes. Curr Cardiol Rev. 2018; 15(2):136-144. PMC: 6520576. DOI: 10.2174/1573403X15666181205110624. View

Tsai W, Lee T, Chen Y, Kao Y, Lu Y, Lin Y . Testosterone replacement increases aged pulmonary vein and left atrium arrhythmogenesis with enhanced adrenergic activity. Int J Cardiol. 2014; 176(1):110-8. DOI: 10.1016/j.ijcard.2014.06.054. View

Chaldoupi S, Loh P, Hauer R, de Bakker J, van Rijen H . The role of connexin40 in atrial fibrillation. Cardiovasc Res. 2009; 84(1):15-23. DOI: 10.1093/cvr/cvp203. View

Sullivan M, Martinez C, Gallagher E . Atrial fibrillation and anabolic steroids. J Emerg Med. 1999; 17(5):851-7. DOI: 10.1016/s0736-4679(99)00095-5. View

Rossi R, Grimaldi T, Origliani G, Fantini G, Coppi F, Modena M . Menopause and cardiovascular risk. Pathophysiol Haemost Thromb. 2003; 32(5-6):325-8. DOI: 10.1159/000073591. View

Odening K, Deiss S, Dilling-Boer D, Didenko M, Eriksson U, Nedios S . Mechanisms of sex differences in atrial fibrillation: role of hormones and differences in electrophysiology, structure, function, and remodelling. Europace. 2018; 21(3):366-376. DOI: 10.1093/europace/euy215. View

Sun Y, Li P, Shi L, Su W, Li D, Xue G . Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice. J Cardiovasc Electrophysiol. 2018; 29(10):1436-1443. DOI: 10.1111/jce.13697. View

10.

Rosenberg M, Shores M, Matsumoto A, Buzkova P, Lange L, Kronmal R . Serum androgens and risk of atrial fibrillation in older men: The Cardiovascular Health Study. Clin Cardiol. 2018; 41(6):830-836. PMC: 6013387. DOI: 10.1002/clc.22965. View

11.

Ko D, Rahman F, Schnabel R, Yin X, Benjamin E, Christophersen I . Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016; 13(6):321-32. PMC: 5579870. DOI: 10.1038/nrcardio.2016.45. View

12.

Tsuneda T, Yamashita T, Kato T, Sekiguchi A, Sagara K, Sawada H . Deficiency of testosterone associates with the substrate of atrial fibrillation in the rat model. J Cardiovasc Electrophysiol. 2009; 20(9):1055-60. DOI: 10.1111/j.1540-8167.2009.01474.x. View

13.

Magnani J, Moser C, Murabito J, Nelson K, Fontes J, Lubitz S . Age of natural menopause and atrial fibrillation: the Framingham Heart Study. Am Heart J. 2012; 163(4):729-34. PMC: 3334861. DOI: 10.1016/j.ahj.2012.01.010. View

14.

Lau D, Stiles M, John B, Shashidhar , Young G, Sanders P . Atrial fibrillation and anabolic steroid abuse. Int J Cardiol. 2007; 117(2):e86-7. DOI: 10.1016/j.ijcard.2006.11.199. View

15.

Berger D, Folsom A, Schreiner P, Chen L, Michos E, ONeal W . Plasma total testosterone and risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Maturitas. 2019; 125:5-10. PMC: 6538393. DOI: 10.1016/j.maturitas.2019.03.015. View

16.

Mathieu S, El Khoury N, Rivard K, Gelinas R, Goyette P, Paradis P . Reduction in Na(+) current by angiotensin II is mediated by PKCα in mouse and human-induced pluripotent stem cell-derived cardiomyocytes. Heart Rhythm. 2016; 13(6):1346-54. DOI: 10.1016/j.hrthm.2016.02.015. View

17.

ONeal W, Nazarian S, Alonso A, Heckbert S, Vaccarino V, Soliman E . Sex hormones and the risk of atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA). Endocrine. 2017; 58(1):91-96. PMC: 5693706. DOI: 10.1007/s12020-017-1385-3. View

18.

Heijman J, Voigt N, Nattel S, Dobrev D . Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014; 114(9):1483-99. DOI: 10.1161/CIRCRESAHA.114.302226. View

19.

Ravens U . Sex differences in cardiac electrophysiology. Can J Physiol Pharmacol. 2018; 96(10):985-990. DOI: 10.1139/cjpp-2018-0179. View

20.

Bretler D, Hansen P, Lindhardsen J, Ahlehoff O, Andersson C, Jensen T . Hormone replacement therapy and risk of new-onset atrial fibrillation after myocardial infarction--a nationwide cohort study. PLoS One. 2013; 7(12):e51580. PMC: 3524193. DOI: 10.1371/journal.pone.0051580. View